Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL16198039 | 0.95 | CYP1A2 (0.52) | CYP1A2KDM4EMAPTRAB9ANPSR1 | |
| SCHEMBL28047152 | 0.81 | ALDH1A1 (0.61) | CYP1A2KDM4EMAPTRAB9ANPSR1 | |
| SCHEMBL9184880 | 0.79 | CYP1A2 (0.60) | CYP1A2KDM4EMAPTRAB9ANPSR1 | |
| SCHEMBL28353965 | 0.79 | PABPC1 (0.51) | KDM4EMAPTRAB9AALDH1A1MEN1 | |
| SCHEMBL5159132 | 0.76 | CES1 (0.52) | NPSR1ALDH1A1CES2BCHEMAOA | |
| SCHEMBL28377273 | 0.76 | ALDH1A1 (0.51) | KDM4EMAPTRAB9ANPSR1ALDH1A1 | |
| SCHEMBL12705657 | 0.75 | CYP1A2 (0.56) | CYP1A2KDM4EMAPTRAB9ANPSR1 | |
| SCHEMBL28158463 | 0.75 | CYP1A2 (0.56) | CYP1A2KDM4EMAPTRAB9ANPSR1 | |
| SCHEMBL14256476 | 0.75 | CYP1A2 (0.50) | CYP1A2KDM4EMAPTRAB9ANPSR1 | |
| Water SCHEMBL28254233 | 0.74 | CES1 (0.50) | NPSR1ALDH1A1CES2BCHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-12038438-B2 | Enzyme quantification | BIO-RAD LABORATORIES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230219043-A1 | DROPLET LIBRARIES | BIO-RAD LABORATORIES, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | disclosed |
| US-11596908-B2 | Droplet libraries | BIO-RAD LABORATORIES, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11534727-B2 | Droplet libraries | BIO-RAD LABORATORIES, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11511242-B2 | Droplet libraries | BIO-RAD LABORATORIES, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-29 | — | — | US | disclosed |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-13 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1091946-B1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTROEM HAKAN VILHELM (NL) | 2004-03-17 | — | — | EP | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
| US-6291494-B1 | 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1086076-A1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065870-A2 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5567411-A | ADMINISTERING TO A WARM-BLOODED ANIMAL TO OBTAIN A MAGNETIC RESONANCE IMAGE OF SUBJECT | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1996-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440881-B2 | Thiosemicarbazates and uses thereof | TST, ABAT, AADAC | CYP1A2 3108/4885KDM4E 2658/4885MAPT 1493/4885 |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CYP1A2 1871/4885KDM4E 1492/4885MAPT 1933/4885 |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CYP1A2 1871/4885KDM4E 1492/4885MAPT 1933/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CYP1A2 1871/4885KDM4E 1492/4885MAPT 1933/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | CYP1A2 3031/4885KDM4E 2783/4885MAPT 3154/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | CYP1A2 3108/4885KDM4E 2658/4885MAPT 1493/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | CYP1A2 2469/4885KDM4E 2649/4885MAPT 1679/4885 |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | CYP1A2 3108/4885KDM4E 2658/4885MAPT 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.